



(51) International Patent Classification:

A61P 31/16 (2006.01) A61K 39/00 (2006.01)
C07K 16/10 (2006.01)

(21) International Application Number:

PCT/US2021/060155

(22) International Filing Date:

19 November 2021 (19.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/117,448 23 November 2020 (23.11.2020) US
63/123,424 09 December 2020 (09.12.2020) US
63/197,160 04 June 2021 (04.06.2021) US
63/261,463 21 September 2021 (21.09.2021) US

(71) Applicants: **VIR BIOTECHNOLOGY, INC.** [US/US];
499 Illinois Street, Suite 500, San Francisco, CA 94158
(US). **HUMABS BIOMED SA** [CH/CH]; Via dei Gaggini
3, 6500 Bellinzona (CH).

(72) Inventors: **CORTI, Davide**; Via dei Gaggini 3, 6500
Bellinzona (CH). **PIZZUTO, Matteo Samuele**; Via dei
Gaggini 3, 6500 Bellinzona (CH). **MINOLA, Andrea**; Via
dei Gaggini 3, 6500 Bellinzona (CH). **CAMERONI, Elis-
abetta**; Via dei Gaggini 3, 6500 Bellinzona (CH). **SNELL,
Gyorgy**; 499 Illinois Street, Suite 500, San Francisco, CA
94158 (US). **FERRI, Elena**; 499 Illinois Street, Suite 500,
San Francisco, CA 94158 (US).

(74) Agent: **MORGAN, John, A.** et al.; Seed Intellectual Prop-
erty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seat-
tle, WA 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: BROADLY NEUTRALIZING ANTIBODIES AGAINST INFLUENZA NEURAMINIDASE




FIG. 41

(57) Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*